Weight Loss · Reference
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
This page covers what REVIVE is, how each half sits next to a GLP-1, why the pairing comes up, the three opposing effects, the symptoms that could come from either, how the schedules fit, and how to add REVIVE properly. Everything here applies to semaglutide the same way.
REVIVE can be prescribed alongside tirzepatide or semaglutide when a physician reviewing your intake judges it appropriate, but no study has tested the blend with a GLP-1, and the blend itself has never been studied as a blend. REVIVE has two halves: GHK-Cu and TB-500, repair peptides with no shared pathway with tirzepatide, and CJC-1295 and ipamorelin, growth hormone secretagogues that pull against a GLP-1 in three places. Ipamorelin acts at the receptor ghrelin uses to signal hunger, it sped gastric emptying in rats where a GLP-1 slows it, and growth hormone reduces insulin sensitivity where GLP-1 medications act the other way. None of that rules the pairing out; it is why appetite and glucose are part of the conversation.
This page covers what REVIVE is, how each half sits next to a GLP-1, why the pairing comes up, the three opposing effects, the symptoms that could come from either, how the schedules fit, and how to add REVIVE properly. Everything here applies to semaglutide the same way.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
The short answer
| Question | Answer |
|---|---|
| Can they be prescribed together? | Yes, when a physician reviewing your intake judges it appropriate |
| Has the combination been studied? | No. Neither REVIVE with a GLP-1, nor REVIVE's four components together |
| Why is it paired? | Recovery and sleep goals, or lean tissue alongside training and protein |
| Does it add weight loss? | No trial shows that; in mice ipamorelin increased body weight, fat and food intake |
| What pulls in opposite directions? | Appetite, gastric emptying in animal work, and glucose |
| What belongs on the intake? | Glucose history, insulin or a sulfonylurea, cancer history, anticoagulants, copper disorders, zinc |
| Same answer for semaglutide? | Yes |
The medications this page covers:
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| REVIVE Blend | 5 mL multi-dose vial: GHK-Cu 10 mg/mL, CJC-1295 1.2 mg/mL, ipamorelin 2.4 mg/mL, TB-500 0.4 mg/mL (50 mg / 6 mg / 12 mg / 2 mg per vial) | 0.25 mL (25 units) under the skin Monday through Friday nights at bedtime | $279/mo |
| Tirzepatide | Dose-specific 2 mL vials at six strengths, 2.5 mg to 15 mg weekly; glycine in the 2.5 mg and 7.5 mg vials | 0.50 mL (50 units) once weekly at every strength | From $159/mo |
| Semaglutide | Dose-specific vials at six strengths, starting with 1 mg per 1 mL at the 0.25 mg starting dose | Printed on the vial for your strength | From $99/mo |
Prices are all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices, set by dose. Compounded medications are not FDA approved.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
What REVIVE is, next to a GLP-1
Tirzepatide is a single peptide that activates the GIP and GLP-1 receptors, acting on appetite, gastric emptying, and insulin and glucagon signalling (what is tirzepatide). REVIVE is four separate peptides in one vial (what is REVIVE). By mass it is mostly GHK-Cu: 50 of the 70 mg.
| Component | Per dose | What it is described to do | Human evidence | Relation to tirzepatide |
|---|---|---|---|---|
| GHK-Cu | 2.5 mg | Collagen and matrix synthesis, copper delivery | Small topical skin studies | No shared pathway |
| CJC-1295 | 0.3 mg | GHRH-receptor signal for a growth hormone pulse | 2006 healthy-adult studies of the long-acting DAC form | Growth hormone reduces insulin sensitivity |
| Ipamorelin | 0.6 mg | Ghrelin-receptor signal for a growth hormone pulse | A 1999 intravenous volunteer study | Hunger signal; faster gastric emptying in rats; glucose |
| TB-500 | 0.1 mg | Actin binding and cell migration, inferred from thymosin beta-4 | None for the fragment | No shared pathway |
The per-dose figures are arithmetic from the vial: 0.25 mL carries a quarter of each per-mL concentration. Because the proportions are fixed, every dose delivers the same split.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
Why the pairing comes up
The live reference on tirzepatide pairings describes growth-hormone-axis peptides as among the common additions to a GLP-1, prescribed with lean tissue in mind as an adjunct to training and protein. The rationale: in the STEP 1 body-composition substudy of semaglutide, both fat mass and lean mass fell, though fat fell by more, and strong appetite suppression makes under-eating protein the default. REVIVE adds a second reason for someone on a weight program who is also training harder and wants the repair peptides for recovery.
What the pairing does not have is evidence that it works. No trial shows a growth hormone secretagogue preserves lean mass during GLP-1 treatment, no trial has measured recovery or sleep on CJC-1295 or ipamorelin, and there is no study of REVIVE or any component with a GLP-1. A protein target and resistance training two to three times a week remain the countermeasures with the most behind them. More in what peptides can you take with tirzepatide.
Where something else fits better
| Situation | Usually a better conversation |
|---|---|
| The growth hormone pulse is the only second goal | CJC-1295 / Ipamorelin, the same two secretagogues in the same ratio |
| Repair is the only second goal | GLOW or KLOW, with no growth hormone component |
| A single tendon or ligament problem | The BPC-157 + TB-500 stack, with far more TB-500 per dose |
| Visceral fat alongside the GLP-1 | Tesamorelin, the growth-hormone-axis peptide with visceral fat trials |
| Stomach side effects on the GLP-1 | A message to your care team; a dose and titration question |
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
The three opposing effects
1. Appetite
Ipamorelin acts at the receptor ghrelin uses to signal hunger, and hunger after a dose is one of the effects reported with REVIVE. In a 2001 mouse study, twice-daily ipamorelin increased body weight, fat-pad weight and food intake. That does not mean a person will gain weight; there are no human data either way. It does mean some people on a GLP-1 notice appetite returning in the evening. Bedtime dosing lands the pulse as you go to sleep, but tell your care team if your appetite changes.
2. Gastric emptying
Ghrelin receptors also sit on the nerves that drive stomach and intestinal movement. In rats, ipamorelin sped gastric emptying; tirzepatide slows it, which is the source of most of its stomach side effects. In the one randomised human trial, of intravenous ipamorelin after bowel surgery, it did not separate from placebo, so the rat effect has not been shown in people, and nobody has studied the two together.
3. Glucose
Growth hormone reduces insulin sensitivity; GLP-1 medications act in the other direction. REVIVE's two secretagogues raise growth hormone, which is why diabetes and impaired glucose tolerance are raised at intake. Prescribing a growth-hormone-axis peptide with a GLP-1 is routine and legitimate, and it is why glucose is watched across both. If you take insulin or a sulfonylurea, low blood glucose on tirzepatide becomes more likely, and that needs to be on your intake too.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
Symptoms that could come from either
| Symptom | On tirzepatide | On REVIVE |
|---|---|---|
| Hunger | Reduced appetite is expected | Hunger after a dose is reported, from ipamorelin |
| Light-headedness or dizziness | 4 to 5% on the approved weight-management label, against 2% | Reported early in some people |
| Headache | Not in the label figures on the tirzepatide side effects page | Reported in the 2006 CJC-1295 trials and with ipamorelin |
| Flushing, warmth or tingling after a dose | Not in the label figures | Common with the secretagogue half |
| Nausea, reflux, constipation | The most common effects, around starting and dose increases | Not commonly described |
| Injection-site redness | 6 to 8% on the label | The most common report |
| A faint blue-green mark at the site | No | Possible, from the copper in GHK-Cu |
| Fluid retention, puffy hands, joint aches | Not in the label figures | A sign of more growth hormone than a person needs |
Start REVIVE when your GLP-1 dose is steady, not in the week of an increase, so a change has one plausible cause. The full REVIVE list is in REVIVE blend side effects.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
Fitting the schedules together
| REVIVE | Tirzepatide | |
|---|---|---|
| Draw | 0.25 mL (25 units on a U-100 insulin syringe) | 0.50 mL (50 units) |
| Medication per dose | 2.5 mg GHK-Cu, 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.1 mg TB-500 | Your weekly strength, 2.5 mg to 15 mg |
| How often | Monday through Friday nights at bedtime, weekends off | Once weekly, same day each week |
| Doses per vial | 20 | 4 |
| One vial lasts | About four weeks | Four weeks |
Both run on a 28-day refill cycle, one vial per fill.
- Two vials, two syringes, two sites. Never mix REVIVE and tirzepatide in one syringe.
- Bedtime is part of the REVIVE schedule. It lands the pulse on the natural nocturnal release; prescribers also direct an empty stomach where possible, because the insulin rise after a meal blunts growth hormone release.
- Keep your tirzepatide day fixed, and use a different site on a shared day.
The unit and milligram chart is in REVIVE blend dosage.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
Who should discuss it first
| Situation | Why |
|---|---|
| Diabetes or impaired glucose tolerance | Growth hormone can raise blood glucose |
| Insulin or a sulfonylurea | Low blood glucose on tirzepatide becomes more likely |
| Personal history of cancer | Growth hormone class concern; TB-500 and GHK-Cu are described around new blood vessel growth |
| Anticoagulant therapy | Raised at intake for REVIVE |
| Wilson's disease or any copper-metabolism disorder | Rules out the GHK-Cu component |
| High-dose zinc supplementation | Competes with copper |
| Personal or family history of medullary thyroid carcinoma or MEN 2 | Rules out tirzepatide and semaglutide |
| Pregnancy, planning pregnancy or breastfeeding | Neither is used |
| Oral contraceptives | May be absorbed less reliably for four weeks after starting tirzepatide and after each dose increase |
| Already on CJC-1295 / Ipamorelin, a GHK-Cu blend or TB-500 | REVIVE would duplicate components |
| Tested athlete | CJC-1295 and ipamorelin are named under S2.2.4 and TB-500 is prohibited too, all at all times |
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
Semaglutide works the same way
Semaglutide acts at GLP-1 only, where tirzepatide acts at GLP-1 and GIP, but it reduces appetite and slows gastric emptying in the same way, so the same three opposing effects apply. Semaglutide and tirzepatide are never taken together; see semaglutide vs tirzepatide.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
How to add REVIVE to a GLP-1 properly
- Name the gap. "I am training more and recovering badly" or "I am worried about losing muscle" gives your physician more to work with than a product name.
- Keep the basics in place. A protein target and resistance training are the countermeasures with the most behind them.
- List glucose history, medications and every blend you take in full.
- Start when your GLP-1 dose is steady, and report appetite changes.
Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. More in can you take two peptides together. Step by step: how to get tirzepatide prescribed, and for the secretagogue half how to get CJC-1295 / Ipamorelin prescribed.
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?
What the evidence shows, honestly
Tirzepatide has a large human trial base in its approved form. REVIVE has never been studied as a blend. Its human evidence belongs to the secretagogue half: small studies showing CJC-1295 and ipamorelin raise growth hormone, and CJC-1295 raises IGF-1. The repair half rests on cell and animal work for TB-500 and GHK-Cu plus small topical GHK-Cu skin studies. There is no study of REVIVE or any component with a GLP-1. On regulation, none of the four is currently in 503A Category 2; the FDA's advisory committee voted against ipamorelin and CJC-1295 in late 2024 for the specific uses it examined, with no final determination issued; TB-500 was recommended for the 503A Bulks List in July 2026 with the final determination pending; and GHK-Cu is scheduled for review before the end of February 2027. The pairing is grounded in mechanism and prescriber experience, which is a reasonable basis for prescribing and not evidence that the combination does better than tirzepatide alone.
References
What this is based on.
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues · Trends Mol Med (2005) · PMID 16099219
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Biomed Res Int (2015) · PMID 26236730
- Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab (2006) · PMID 16352683
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial · JAMA (2021) · PMID 33755728
- Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine (2016) · PMID 27633186
- Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · The Lancet (2021) · PMID 33667417
- Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · Nature Medicine (2022) · PMID 36216945
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial · JAMA (2022) · PMID 35015037
- Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · New England Journal of Medicine (2025) · PMID 40353578
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
Can You Take REVIVE Blend With Tirzepatide or Semaglutide?, answered.
It can be prescribed alongside tirzepatide when a physician reviewing your intake judges it appropriate. No study has tested the combination, and appetite and glucose are watched because of the secretagogue half.
Yes, on the same reasoning and with the same cautions about appetite and glucose.
It might. Its ipamorelin acts at the receptor ghrelin uses to signal hunger, and hunger after a dose is reported. Tell your care team if your appetite changes.
No trial shows a growth hormone secretagogue preserves lean mass during GLP-1 treatment. Protein and resistance training are the countermeasures with evidence.
No. None of its components is a weight treatment, and the animal evidence on ipamorelin and body fat runs the other way. For weight, the GLP-1 is the medication with the evidence.
It can. Growth hormone raises blood glucose, while GLP-1 medications act the other way. That is why glucose history is raised at intake and watched across both.
Yes, as two separate injections from two separate vials, each with its own syringe and at a different site.
Neither has been studied with one. CJC-1295 / Ipamorelin is the secretagogue half on its own; REVIVE adds GHK-Cu and a small amount of TB-500 for someone with a repair or skin goal as well.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.